B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
DTIL
Precision BioSciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.80
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-30
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+42.8
Score
AI commentary
Company updates are constructive on trial execution, including August DMD first dosing, but the supplied evidence does not establish a sustained post-release price reaction or verified analyst revisions. Social, options, short-interest and employee-sentiment coverage is unavailable; the zero fields above indicate unavailable measurements, not neutral readings. The deterministic prior has turned negative since the June baseline, supporting a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-09-30
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31eventYear-end PBGENE-HBV clinical updateHigh impact
Precision targets an ELIMINATE-B update by year-end 2026. Earlier biopsy and blood-biomarker findings support interest, but the small early-stage dataset leaves durability, safety and dose selection unresolved [#SEC-8K-2026-08-06].
2026-12-31eventFirst FUNCTION-DMD safety dataHigh impact
The first PBGENE-DMD patient was dosed in August, and Precision expects initial Phase 1/2 safety data by year-end 2026. This is a trial-execution milestone, not yet evidence of clinical efficacy [#8-K-2026-08-24] company release.
2027-06-30catalystRunway depends on clinical spending and financing accessHigh impact
June 30 cash, cash equivalents and restricted cash were $112.4 million, down from $137.2 million at year-end 2025. Precision expects runway through 2028, citing operating discipline and availability of its at-the-market facility; dilution remains a risk [#SEC-8K-2026-08-06] company earnings release.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-30 • Updated nightlySource: Internal modelMethodology